Digital chatbot Woebot lands FDA breakthrough designation to tackle postpartum depression

Digital mental health company Woebot Health has landed FDA Breakthrough Device Designation for its postpartum depression digital therapeutic, WB001.

WB001 combines cognitive behavioral therapy and elements of interpersonal psychotherapy with the company's conversational chatbot, Woebot, to deliver treatment directly through patients' phones.